anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bariatric surgery is currently the most effective long-term treatment for morbid obesity as well as type-2 diabetes mellitus. The field of metabolic and bariatric surgery has seen tremendous growth over the past decade with dramatically reduced risks. This article aims to provide an update on bariatric surgery, highlighting the latest outcomes, improvements, and challenges in the field. Recently, the American Society of Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) released a major update to the indications for bariatric surgery at BMI ≥35 kg/m2 regardless of co-morbidities and 30-34.9 kg/m2 with obesity-related comorbidities. Sleeve gastrectomy has emerged as the most popular bariatric procedure in the last 10 years with its remarkable efficacy and safety profile. The implementation of the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) and Enhanced Recovery After Surgery (ERAS) protocols have significantly improved the quality of care for all bariatric patients. The recent introduction and FDA approval of Glucagon-Like Peptide-1 (GLP-1) agonists for chronic obesity has garnered significant media coverage and popularity, but no guidelines exist regarding its use in relation to bariatric surgery. This update underscores the need for tailored approaches, ongoing research, and the integration of evidence-based medicine and innovations to enhance patient care.
A system provides a web site through which physicians can access information about multiple drugs provided by multiple drug companies. A user is authenticated as being a registered physician before being allowed access to the system. The system provides an interactive on-line detail or marketing presentation of a drug. The interactive detail provides information about a drug in addition to requesting and receiving responses or input from the user participating in the interactive detail. Questions and challenges are presented to the user to reinforce concepts, such as a drug's mechanism of action, that are presented to the user during the detail. Users' responses to interactive details are accumulated and provided to the respective drug companies that sponsor the details. As an incentive, the system provides an honorarium or gift to targeted users upon completion of interactive presentations.
BACKGROUND: Tacrolimus blood level variability is associated with reduced graft survival among kidney transplant recipients. To date, no practical approach for reducing variability has been validated. We defined specific tacrolimus blood level patterns correlated with variability and evaluated their independent association with reduced graft survival.
METHODS: In this single-center retrospective study, we predefined 12 patterns that exhibited correlation with high tacrolimus blood level variability. Subsequently, we utilized a multivariate Cox proportional hazard model, in conjunction with the Akaike information criteria, to evaluate the association between the predefined patterns and decreased graft survival.
RESULTS: Our cohort included 1305 kidney transplant recipients. The primary outcome of this trial was graft loss, defined as the initiation of chronic dialysis or the need for retransplantation. The secondary outcome was the combination of death-censored graft loss and death with a functioning graft. During the study's follow-up period, there were 131 events of graft loss. The number of episodes of subtherapeutic tacrolimus level during the first-year posttransplantation was significantly associated with graft loss (HR 1.208 per episode, 95% CI 1.075-1.356, p = 0.001) and significantly improved the relative likelihood of the model compared to the multivariate model as demonstrated by the delta AIC value (8.256, p = 0.016).
CONCLUSION: In addition to increased tacrolimus blood level variability, the number of episodes of subtherapeutic tacrolimus levels is independently associated with decreased graft survival among kidney transplant recipients.
The most common cause of chronic gastritis is Helicobacter pylori, which can also cause serious gastroduodenal diseases in some patients. These include gastric cancer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and gastric and duodenal peptic ulcer disease (PUD). Strong correlations have been shown between H. pylori and a number of extra-gastric illnesses, including vitamin B12 deficiency, idiopathic thrombocytopenic purpura, and unexplained iron-deficiency anemia. Identifying and eliminating H. pylori in people suffering from these conditions is also advised. Furthermore, neurological disorders, cardiovascular disorders, hepatobiliary disorders and autoimmune disorders may be associated with H. pylori infection. Age, ethnicity, degree of hygiene, and social and economic circumstances are risk factors for H. pylori infection An elevated prevalence of gastrointestinal diseases or symptoms (for example, dyspeptic symptoms) in populations where H. pylori infection is high, implies that a large number of subjects receive primary health care.Therefore, it is essential that primary care physicians have the appropriate knowledge for making adequate decisions and preventing incorrect practices that result in elevated costs and absolutely no health benefits for the population.

Since day-to-day clinical practice demonstrates that many healthcare disciplines surprisingly deal with H. pylori infection in the absence of local guidelines on this matter, there has been no study conducted in Sohag Governate evaluated knowledge, practice and attitude about H. pylori among healthcare physicians as of the time I conducted this survey.
The present invention provides an improved mode of operation of an apparatus for angioplasty or cardiac catheterization, apparatus for angioplasty and cardiac catheterization, and method of angioplasty or cardiac catheterization. The improvement and improved mode of operation includes the step of administering a therapeutically effective amount of a lipid acceptor during angioplasty or cardiac catheterization of a subject with the apparatus or component thereof. The lipid acceptor is selected from the group consisting of a large liposome comprised of phospholipids substantially free of sterol and small acceptors. The effective period of time is in the range of about less than 1 minute to about two years from the time of the angioplasty or cardiac catheterization. The improved angioplasty or cardiac catheterization apparatus includes means for administering a therapeutically effective amount of a lipid acceptor, and optional co-administration means for administering the lipid acceptor and a diagnostic agent. The improved mode of operating an angioplasty or cardiac catheterization apparatus includes administering a therapeutically effective amount of a lipid acceptor from the apparatus or component thereof into a vessel of a subject by administration means. The invention further provides a method of diagnosing a side-effect of reverse transport of cholesterol from peripheral tissues to the liver in vivo accompanying parenteral administration of a multiplicity of large liposomes and small liposomes during a treatment period. The method includes the step of periodically assaying plasma atherogenic lipoprotein concentrations with an assay to obtain an assayed atherogenic lipoprotein concentration.
An economical prescription order tracking system automatically monitors and tracks prescription orders through a conventional pharmacy. The system includes a tracking tag having a unique identifier associated with it secured near the prescription order such that it travels with the order through various locations within the pharmacy. Tag reading devices are positioned at key locations throughout the pharmacy to detect the location of each tag, and its associated attached prescription order. The detected locations are compiled via a computer system and associated with the customer, such that at any given time the location of the prescription order within the pharmacy can be determined, thereby facilitating the efficient operation of the pharmacy. Preferably, filled prescription orders are placed in a large bin having multiple cubbies within it. Each cubby has a displayed number and a tag reading device received therein such that the location of the prescription order within the cubby is easily determined simply by placing the prescription order with tag into an available cubby. The time each prescription order remains at each location and worker identity information at each location can be recorded and compiled to facilitate workflow and worker efficiency monitoring of the pharmacy.
All patients in the control arm will receive best medical therapy including start or optimization of secondary preventive pharmacotherapy, smoking cessation advise and advise on modifiable risk factors. The control arm will also receive an information leaflet about relevant lifestyle modifications for PAD. After the baseline measurements and data collection, there will be no scheduled visits to a health care provider until week 12.
Microgestin 24 Fe is a combination oral contraceptive for oral administration consisting of active tablets containing norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, and placebo tablets containing ferrous fumarate, which serve no therapeutic purpose.

  * Each active pale yellow tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Inactive ingredients include polyvinyl alcohol, titanium dioxide, talc, macrogol/polyethylglycol 3350 NF, lecithin (soya), D&C Yellow No.10 Aluminum Lake, FD&C Blue No.2 Aluminum Lake, FD&C Yellow No.6 Aluminum Lake, lactose, magnesium stearate and pregelatinized corn starch.
  * Each placebo brown tablet contains 75 mg ferrous fumarate, polyvinyl alcohol, iron oxide yellow, talc, macrogol/polyethylene glycol 3350 NF, iron oxide red, lecithin (soya), iron oxide black, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate and crospovidone.. The ferrous fumarate tablets do not serve any therapeutic purpose. Ferrous fumarate tablets are not USP for dissolution.



The chemical name of ethinyl estradiol is 19-nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. The empirical formula of ethinyl estradiol is C20H24O2 and the structural formula is:

The chemical name of norethindrone acetate is 17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate. The empirical formula of norethindrone acetate is C22H28O3 and the structural formula is:
Injectable insulin preparations with protracted effect, wherein pure insulin is used in a crystalline state, are obtained by producing an insulin crystal suspension exhibiting per litre a total content of one or more of the metals zinc, cobalt, nickel, cadmium, copper, manganese and iron above 7.5XAX10-3 millequivalent, where "A" indicates the number of international units of insulin per millilitre of the suspension.  Insulin crystals may be suspended in an aqueous medium containing one or more of the above metals in the form of a salt such as chloride, sulphate, nitrate or acetate, a hydroxide, oxide, metal complex or metal per se and having, or being adjusted to, a pH of 3 to 9, and preferably 7, provided substances suppressing the solubility of the crystals are not present.  The medium is preferably rendered isotonic with e.g. glucose, glycerin and sodium chloride.  The insulin crystals are preferably of at least 10m , especially 25 to 100m , in which case a stabilizer, e.g. a high molecular polysaccharide such as dextran should be present.  The pH is maintained by buffers such as an acetate, borate, diethylbarbiturate, phosphate, or maleate buffer or a mixture thereof.  Phosphate buffers are not suitable for zinc insulin crystals, but may be used for nickel insulin crystals. Preservatives such as phenol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate and phenyl mercuric acetate may be present.  The suspension medium may contain dissolved or precipitated amorphous insulin, or such may be provided by the added insulin crystals. Insulin crystals with increased content of one or more of the mentioned metals may be suspended in a medium such as water or fatty oils such as olive, sesame and peanut oil which does not per se show any content of the metals in question.  The suspension medium and the insulin crystals may be packed in separate ampoules.
The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. In group I, FV EnamelastTM will be applied to all teeth using compressed air and cotton rolls, leaving them to dry for one minute. Patients will be advised to avoid eating, drinking, or brushing for 3-4 hours after application.
The invention relates to a silkworm skin-rejuvenation protein emulsion and a manufacture method thereof, relating to the technical field of biological skin caring products. The invention comprises monoglyceride, stearic acid, enriched water, whiting gene and water. The component also includes silkworm biological protein liquid, EAP collagen free factor, CES cation protein and phytin. First, the silkworm biological protein liquid is prepared, and then the silkworm biological protein liquid, monoglyceride and stearic acid are put by ratios into an enamel reactor to be heated into boiling state so as to form matter A. The matter A is cooled to 45 DEG C, and then the enriched water and the whiting factor are added into the matter A so as to form matter B. The matter B is cooled into the normal temperature, then the EAP collagen free factor, the CES cation protein and the phytin are added and stirred evenly with the matter B until a white and fine cream C is formed. In the end, water is added into the cream for evenly stirring. The invention can enhance the cell energy so as to prolong the cell life, thus having distinct anti-aging effect. The invention really meets the present fashion and scientific trend which is healthy, green and environment-friendly.
This is the only arm of the study. It is a 6 week period where the participants will either be using night splints or the TESS device to treat their plantar fasciitis symptoms.
Zanaflex use has been associated with hallucinations. Formed, visual hallucinations or delusions have been reported in 5 of 170 patients (3%) in two North American controlled clinical studies. Most of the patients were aware that the events were unreal. One patient developed psychosis in association with the hallucinations. One patient among these 5 continued to have problems for at least 2 weeks following discontinuation of tizanidine. Consider discontinuing Zanaflex in patients who develop hallucinations.
A system and method include a battery removably coupleable to a medical device. The battery includes a cell for storing an electrical charge, a housing, a first contact, and a second contact that is inactive when the battery is not in proximity to the medical device. The battery includes a sensor for generating a proximity signal in response to a proximity of the medical device to the battery that is not based on an electrical connection of the medical device to the contacts. The battery includes a battery controller for receiving the proximity signal, and responsively causing the second contact to be activated. One of the medical device and the battery comprises a communication device. When the medical device is coupled to the battery and the second contact is activated, the communication device transmits an authentication signal to enable authentication.
PURPOSE:To provide an antiserum containing an antibody against a specific mustard compound and capable of selectively destructing a cancer tissue. CONSTITUTION:The objective antiserum contains an antibody against the compound of formula I [R is alkyl or group of formula II - formula VII (Z is formyl or acetyl; R1, R3, R4, R6 and R7 are H or alkyl; R2 is alkyl, benzyl or alkoxycarbonyl; R5 is alkylene; n and n' are 0-2)], e.g. N-[3-(p-[bis(2- chloroethyl)-amino]-phenyl)-N-formyl-DL-alan-yl]valine. The above compound is injected into a cancer tissue beforehand and said antiserum is administered to the patient to effect the antigen-antibody reaction in or near the cancer tissue to break the tissue. Cancer can be cured irrespective of the kind of the cancer without being influenced with a cancer antigen in blood. It is not necessary to determine the specific antigen of the cancer of the patient itself not taking consideration of the subcluster of the cancer cells.
The present invention relates to the field of compositions of matter, disclosing compositions of matter which as aqueous solutions, may be used to perfuse a living or non-living subject in need of perfusion. The solutions according to the invention are typified by an aqueous solution comprising a polysaccharide oncotic agent, a physiologically compatible buffer, a simple hexose sugar, dissolved chloride salts of calcium, sodium and magnesium, and a dissolved organic salt of sodium. The solutions according to the invention are effective substitutes for blood. In addition the solution according to the invention may be used to preserve the biological integrity of the organs of a mammalian donor organism as shown by superior anatomical integrity of cryopreserved organs and tissues of subjects perfused with the solution of the invention. The solutions may be used for a number of purposes including maintaining a partially or substantially completely exsanguinated subject at temperatures substantially below those normally maintained by a mammal. The solutions may be used in conjunction with hyperbaric environments to maintain such partially or completed exsanguinated subjects alive without infusing blood back into the subject. Methods for using the solutions for these purposes are disclosed.
Patients receive metformin hydrochloride PO BID and standard chemotherapy for 6 -8 cycles. Treatment with metformin hydrochloride continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
PURPOSE: To obtain a microcapsule for a food and a drug containing casein as a wall film substance by a method wherein a solid or oils or fats hardly soluble in water is dispersed in an aqueous casein solution and milk coagulating enzyme is added thereto to coagulate the casein around a dispersed substance as para-casein and the resultant microcapsule is warmed. CONSTITUTION:A solid or oils or fats hardly soluble in water is dispersed in an aqueous solution containing casein as a core substance in an amount of about 0.5- 5%. To the resultant dispersion, a mild coagulating enzyme such as calf rennet,  bacterial rennet, pepsin, trypsin, papain or the like is added in an amount of about 0.001-0.01mol and, thereby, casein is coagulated around the core substance as  para-casein. When the resultant dispersion is slowly warmed to a temp. of 35- 45 deg.C, para-casein is fixed to form a microcapsule. Further, prior to acting the milk  coagulating enzyme, casein may be gathered to a periphery of the core substance by coacervation or difference of solubility.
Ischemic stroke followed by reperfusion (IR) leads to extensive cerebrovascular injury characterized by neuroinflammation and brain cell death. Inhibition of matrix metalloproteinase-3 (MMP-3) emerges as a promising therapeutic approach to mitigate IR-induced stroke injury. We employed middle cerebral artery occlusion with subsequent reperfusion (MCAO/R) to model ischemic stroke in adult mice. Specifically, we investigated the impact of MMP-3 knockout (KO) on stroke pathophysiology using RNA sequencing (RNA-seq) of stroke brains harvested 48 h post-MCAO. MMP-3 KO significantly reduced brain infarct size following stroke. Notably, RNA-seq analysis showed that MMP-3 KO altered expression of 333 genes (252 downregulated) in male stroke brains and 3768 genes (889 downregulated) in female stroke brains. Functional pathway analysis revealed that inflammation, integrin cell surface signaling, endothelial- and epithelial-mesenchymal transition (EndMT/EMT), and apoptosis gene signatures were decreased in MMP-3 KO stroke brains. Intriguingly, MMP-3 KO downregulated gene signatures more profoundly in females than in males, as indicated by greater negative enrichment scores. Our study underscores MMP-3 inhibition as a promising therapeutic strategy, impacting multiple cellular pathways following stroke.
PURPOSE:To provide an antitussive having a strengthened antitussive activity and not manifesting an adverse effect deteriorating the body dependency-forming ability of the antitussive by compounding L-tryptophan as an active ingredient. CONSTITUTION:1 pt.wt. of an antitussive ingredient is compounded with 2-50 pts.wt. of L-tryptophan and suitably with other conventional additives such as an excipient, a carrier, a diluent, etc., followed by preparing the mixture into the objective antitussive by a conventional method. The antitussive ingredient is one or more selected from dihydrocodeine, noscapine and dextromethophan. The antitussive can be prepared in a shape of an oral administration agent such as powder, syrup, tablets or granules or in a shape of a parenteral agent such injection or suppository.
Chronic Hepatitis B virus (CHB) infection is a global health challenge, causing damage ranging from hepatitis to cirrhosis and hepatocellular carcinoma. In our study, single-cell RNA sequencing (scRNA-seq) analysis was performed in livers from mice models with chronic inflammation induced by CHB infection and we found that endothelial cells (ECs) exhibited the largest number of differentially expressed genes (DEGs) among all ten cell types. NF-κB signaling was activated in ECs to induce cell dysfunction and subsequent hepatic inflammation, which might be mediated by the interaction of macrophage-derived and cholangiocyte-derived VISFATIN/Nampt signaling. Moreover, we divided ECs into three subclusters, including periportal ECs (EC_Z1), midzonal ECs (EC_Z2), and pericentral ECs (EC_Z3) according to hepatic zonation. Functional analysis suggested that pericentral ECs and midzonal ECs, instead of periportal ECs, were more vulnerable to HBV infection, as the VISFATIN/Nampt- NF-κB axis was mainly altered in these two subpopulations. Interestingly, pericentral ECs showed increasing communication with macrophages and cholangiocytes via the Nampt-Insr and Nampt-Itga5/Itgb1 axis upon CHB infection, which contribute to angiogenesis and vascular capillarization. Additionally, ECs, especially pericentral ECs, showed a close connection with nature killer (NK) cells and T cells via the Cxcl6-Cxcr6 axis, which is involved in shaping the microenvironment in CHB mice livers. Thus, our study described the heterogeneity and functional alterations of three subclusters in ECs. We revealed the potential role of VISFATIN/Nampt signaling in modulating ECs characteristics and related hepatic inflammation, and EC-derived chemokine Cxcl16 in shaping NK and T cell recruitment, providing key insights into the multifunctionality of ECs in CHB-associated pathologies.